Rapid Micro Biosystems Inc Overview
Industry: Medical Devices
Sector: Healthcare
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, onsite technical training, and customer support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. In addition, it offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; and RMBNucleus Central Manager portal streamlines monitoring and reporting. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts. Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, and internationally. The company offers Growt Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Rapid Micro Biosystems Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $8M (reported); EPS was $0.31 (reported).
What changed
- Revenue reported to $8M; EPS reported to $0.31.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Form 4 Rapid Micro Biosystems Inc For: 24 July By Investing.com
Headline from Investing.com South Africa: Form 4 Rapid Micro Biosystems Inc For: 24 July By Investing.com.
Form 4 Rapid Micro Biosystems Inc For: 24 July By Investing.com
Headline from Investing.com Canada: Form 4 Rapid Micro Biosystems Inc For: 24 July By Investing.com.
Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
Headline from GlobeNewswire: Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.